Comment
doi: 10.1016/S0140-6736(19)31513-2.
Epub 2019 Jul 4.
Interleukin-23 blockade: another breakthrough in the treatment of psoriasis
Affiliations
- PMID: 31280968
- DOI: 10.1016/S0140-6736(19)31513-2
Item in Clipboard
Comment
Interleukin-23 blockade: another breakthrough in the treatment of psoriasis
Lancet.
.
No abstract available
Comment on
-
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Lancet. 2019. PMID: 31280967 Clinical Trial.
Similar articles
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057361 Clinical Trial.
-
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646. N Engl J Med. 2015. PMID: 26154787 Clinical Trial.
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057360 Clinical Trial.
-
A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.Skin Therapy Lett. 2017 Mar;22(2):8-10. Skin Therapy Lett. 2017. PMID: 28329405 Review.
-
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.Semin Cutan Med Surg. 2010 Mar;29(1):48-52. doi: 10.1016/j.sder.2010.02.001. Semin Cutan Med Surg. 2010. PMID: 20430307 Review.
Cited by
-
Recent Update on Immunopathogenesis of Psoriasis.Indian J Dermatol. 2022 Jul-Aug;67(4):360-373. doi: 10.4103/ijd.ijd_569_22. Indian J Dermatol. 2022. PMID: 36578729 Free PMC article.
-
Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway.Mediators Inflamm. 2020 Apr 28;2020:1719467. doi: 10.1155/2020/1719467. eCollection 2020. Mediators Inflamm. 2020. PMID: 32410846 Free PMC article.
-
Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis.EMBO Mol Med. 2022 Mar 7;14(3):e14455. doi: 10.15252/emmm.202114455. Epub 2021 Dec 22. EMBO Mol Med. 2022. PMID: 34936223 Free PMC article.
-
Cyclic AMP Response Element Modulator-α Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis.J Immunol. 2021 Jul 1;207(1):55-64. doi: 10.4049/jimmunol.2100240. Epub 2021 Jun 16. J Immunol. 2021. PMID: 34135066 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
